A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia | Leukemia
FLAG-IDA chemotherapy for leukemia- AML | ChemoExperts
Prevention and Treatment of Cytarabine-Induced Keratoconjunctivitis
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Cytarabine Dose for Acute Myeloid Leukemia | NEJM
Fernand Bteich on X: "13/ Typical induction regimen is 7+3. Total is 7 days with 3 days of overlap. 7 days of cytarabine infusion. 3 days of anthracycline infusion (daunorubicin or idarubicin).
1930-R-MPV/high dose cytarabine overview | eviQ
High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3 - ScienceDirect
Cytarabine Dose for Acute Myeloid Leukemia | NEJM
Cytarabine - Wikipedia
For relapsed ALL patients under 65 years of age, the salvage... | Download Scientific Diagram
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect
Cytarabine Dose for Acute Myeloid Leukemia | NEJM
Core binding factor acute myelogenous leukemia-2021 treatment algorithm | Blood Cancer Journal
Acute myeloid leukaemia (AML) and cytarabine pharmacogenomics
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial -
IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review
Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
JCM | Free Full-Text | Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Chemotherapy pre-treatment sensitizes AML cells to DNT-mediated... | Download Scientific Diagram
